Increase resilience for lymphoma survivors after treatment
Official title: Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Run by Massachusetts General Hospital · NCT07014293 · Data updated 2026-11-12
A mind-body group program is tested to see if it helps early post-treatment lymphoma survivors cope better than usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 254 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | September 3, 2026 |
| Main results expected | July 1, 2030 |
| Study ends | July 1, 2030 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT07014293 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older, English-speaking, who are at least 6 months post-diagnosis and have either ongoing treatment response or disease control within 2 years after completing treatment.
✕Probably not a fit
Individuals with uncontrolled or progressive lymphoma during the study or those unable to participate via telehealth may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial tests the SMART3RP-Lymphoma mind-body resilience program against enhanced usual care in 254 adults who are in early survivorship after lymphoma treatment. The intervention blends cognitive-behavioral, positive psychology, and relaxation techniques to improve coping with chronic stress related to survivorship. Outcomes focus on coping skills, with exploratory analyses looking at how factors like age, sex, race/ethnicity, and living situation may influence responses. The study is led by Massachusetts General Hospital and conducted within Mass General Brigham sites in Boston, MA. Results will inform whether structured psychosocial support can improve adjustment after lymphoma treatment.
Why it matters
Potential benefit: If successful, participants may experience improved coping and resilience during the transition to survivorship.
How similar studies have gone: Previous mind-body and resiliency programs have shown benefit in coping and stress management in cancer survivorship populations, supporting the approach's potential.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * English speaking adult (18 years or older at enrollment) * Is at least 6 months post-diagnosis and a) is currently undergoing lymphoma treatment (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) with evidence of treatment response or disease control; or b) has completed lymphoma treatment (e.g., chemotherapy/immunotherapy/radiation therapy, surgery or other) within the past 2 years and has disease control at treatment completion; patients may still be on maintenance treatment to prolong disease control. Exclusion Criteria: * Has not initiated treatment for lymphoma. * Has worsening, progressive, or uncontrolled disease that is not responding to treatment. * Active Psychiatric, medical or cognitive comorbidity as determined by site PI or treating clinician * Unwilling or unable to participate using telehealth platform
Where it's running
-
Mass General Brigham
Boston, Massachusetts, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma
This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.